StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report published on Sunday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Trading Down 1.2 %

EVOK stock opened at $4.90 on Friday. The firm has a 50-day moving average of $4.95 and a two-hundred day moving average of $5.28. The firm has a market capitalization of $7.28 million, a PE ratio of -0.45 and a beta of 0.16. Evoke Pharma has a one year low of $3.54 and a one year high of $14.04.

Hedge Funds Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent SEC filing.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.